Treating cancer more selectively and more effectively – this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU). The process transforms proteins and antibodies into stable, highly functional drug transporters, with which tumor cells can be detected and killed.
Classic chemotherapy for the treatment of cancer is based on toxic substances that are particularly effective for rapidly dividing cells. However, since healthy tissue also depends on cell division, treatment with chemotherapeutic substances is often accompanied by severe side effects. A dose sufficient to completely remove the tumor, would in many cases be too toxic to administer to a diseased person. With more modern approaches, it is now possible to transport active agents (drugs) in the body selectively to the site of action, for example by linking a drug with an antibody that can differentiate cancer cells from healthy tissue through changes on the surface of the cell. Five such Antibody Drug Conjugates (ADCs) are already on the market.
However, these ADCs lose a large part of their “toxic cargo” en route to the cancer cell. The substances (drugs) are released into the bloodstream and dangerous side effects can occur. A stable link between drug and antibody would therefore be highly desirable. This is precisely what the researchers – a team led by Professor Christian Hackenberger from the FMP and Professor Heinrich Leonhardt from the LMU Biocenter – focused on. Their results have been published in the prestigious journal, Angewandte Chemie: In two consecutive articles, the development of methods and the application of these methods to selective drug transport are presented.
The new drug transporters enable lower doses and less severe side effects
“We have developed an innovative technology that makes it possible to link native proteins and antibodies to complex molecules, such as fluorescent dyes or drugs more easily and with better stability than ever before,” reports Marc-André Kasper, a researcher in Christian Hackenberger’s group. The researchers discovered the outstanding properties of unsaturated phosphorus (V) compounds and took advantage of those. These phosphonamidates connect a desired modification – for example, a cancer-fighting agent – exclusively to the amino acid cysteine, in a protein or antibody. Since cysteine is a very rare natural occurring amino acid, the number of modifications per protein can be controlled quite effectively, which is essential for the construction of drug conjugates. In addition, phosphonamidates can easily be incorporated into complex chemical compounds. “The greatest achievement of the new method, however, is that the resulting bond is also stable during blood circulation,” says Marc-André Kasper. The ADCs that are on the market cannot achieve this.
To test the applicability on targeted drug delivery, the researchers compared their technology directly with the FDA-approved ADC, Adcetris®. The medication was re-created as precisely as possible with the same antibody and active agent, the only difference was that the innovative phosphonamidate linkage was used. When applied to blood serum, the researchers observed that their modified ADC lost significantly less active ingredient over a period of days. They also used the new technology in experiments with mice to combat Hodgkin’s lymphoma. The preparation proved to be more effective than the conventional medication. “From our results, we conclude that phosphonamidate-linked drug transporters can be administered in lower doses, and that side effects can be further reduced. Thus the technology has great potential to replace current methods in order to develop more effective and safer ADCs in the future,” says FMP group leader Christian Hackenberger.
In the next step, the research groups will continue their efforts in the development of ADCs based on phosphonamidates. Preclinical studies, which are essential for the treatment of patients, are already underway. In this regard, the promising start-up company Tubulis, which was awarded the Leibniz Start-Up Prize last year, functions as a platform for the further development to market maturity.
The Latest on: Antibody Drug Conjugates
[google_news title=”” keyword=”Antibody Drug Conjugates” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antibody Drug Conjugates
- Innovent, Synaffix expand ADC collaboration following positive preliminary clinical signal from ongoing phase 1 studyon December 8, 2023 at 2:30 am
Innovent, Synaffix expand ADC collaboration following positive preliminary clinical signal from ongoing phase 1 study: Rockville, Maryland Friday, December 8, 2023, 16:00 Hrs [IST ...
- MBrace Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Antibody Drug Conjugate at 2023 San Antonio Breast Cancer Symposiumon December 7, 2023 at 11:53 pm
La Merie Publishing prepares brief and full reports as well as competitor analysis reports, the latter in a tabulated format with structured listings of industry-relevant data. One of our top-selling.
- EnGeneIC granted FDA “Fast-Track” Designation for Novel Armed Nanocell Drug Conjugate (ANDC) Pancreatic Cancer Therapeuticon December 7, 2023 at 4:50 pm
EnGeneIC, an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology, has achieved a significant milestone with the granting of FDA “Fast-Track” designation ...
- Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Studyon December 6, 2023 at 5:00 pm
Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index ...
- An Important History Lesson for Gene-Editing Investorson December 2, 2023 at 5:48 am
The history of weight-loss drugs and ADCs shows that biotech innovation is not a linear process but a complex and dynamic one that requires a tremendous amount of patience. However, for those who do ...
- Abbvie's $10bn swoop puts the spotlight on antibody-drug conjugates stockson December 1, 2023 at 12:23 am
AbbVie Inc has announced the acquisition of ImmunoGen (NASDAQ:IMGN) for $10.1 billion in cash - a deal that takes it into the world of antibody-drug conjugates (ADC), which target cancer cells more ...
- AbbVie signs $10 billion deal to buy cancer drugmaker ImmunoGenon November 29, 2023 at 11:45 pm
Elahere is part of a new class of cancer drugs called antibody drug conjugates (ADC), which comprise a monoclonal antibody that precisely targets cancer cells and reduces toxicity of other cells. Due ...
- The clinical development of antibody-drug conjugates for non-small cell lung cancer therapyon November 28, 2023 at 3:35 pm
Antibody-drug conjugates (ADCs), a revolutionary class of antitumor drugs, have displayed promising clinical outcomes in cancer treatment. In 2022, trastuzumab deruxtecan (Enhertu) was approved for ...
- Antibody-drug conjugateon November 27, 2023 at 4:00 pm
Researchers from Multitude Therapeutics Inc. have reported the preclinical profile of AMT-253, a MUC18-targeting antibody-drug conjugate (ADC) under development for the treatment of melanoma. It ...
- Leading innovators in antibody-drug conjugates for the pharmaceutical industryon November 15, 2023 at 10:07 am
Antibody-drug conjugates (ADCs) are a type of targeted cancer therapy that combine the specificity of monoclonal antibodies (mAbs) with the cytotoxic effects of chemotherapeutic drugs. In an ADC, a ...
via Bing News